Stock Analysis

Eiken Chemical Third Quarter 2025 Earnings: EPS: JP¥23.40 (vs JP¥25.69 in 3Q 2024)

TSE:4549
Source: Shutterstock

Eiken Chemical (TSE:4549) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥10.9b (up 6.7% from 3Q 2024).
  • Net income: JP¥807.0m (down 15% from 3Q 2024).
  • Profit margin: 7.4% (down from 9.3% in 3Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: JP¥23.40 (down from JP¥25.69 in 3Q 2024).
earnings-and-revenue-growth
TSE:4549 Earnings and Revenue Growth February 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eiken Chemical Earnings Insights

Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Japan.

Performance of the Japanese Medical Equipment industry.

The company's shares are down 2.2% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Eiken Chemical that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Eiken Chemical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:4549

Eiken Chemical

Engages in the manufacturing and sale of clinical diagnostics in Japan.

Excellent balance sheet with moderate growth potential.

Community Narratives

Leading the Game with Growth, Innovation, and Exceptional Returns
Fair Value SEK 300.00|49.486999999999995% undervalued
Investingwilly
Investingwilly
Community Contributor
Why ASML Dominates the Chip Market
Fair Value €864.91|16.442% undervalued
yiannisz
yiannisz
Community Contributor
Global Payments will reach new heights with a 34% upside potential
Fair Value US$142.00|20.528% undervalued
Maxell
Maxell
Community Contributor